In the publication of this article [1] , there are two corrections: 1. The corresponding author Yuanzhong Chen's email should be changed to chenyz@mail.fjmu.edu.cn; 2. Several figures Fig. 5, Fig. 8 , and Additional files 5, 6, 9 and 10 need to be corrected, because the formats are wrong, and the revised figures are shown below.
The original article has been corrected.
Additional files
Additional file 5: Figure S5 . Homoharringtonine (HHT) combined with arsenic trioxide (ATO) decrease the proportion of primary leukemia stem cells (LSCs) in serum free medium with cytokine cocktail (Flt3L, SCF, IL-3 and IL-6). Quantification of frequencies of CD34+cells (A), CD34+/CD38 −cells (B) and CD34+/CD38−/CD96+ cells (C) from patient 4. (D) Display of flow cytometric analysis on bone marrow sample after treatment with HHT and ATO alone or combined.
Additional file 6: Figure S6 . Homoharringtonine (HHT) combined with arsenic trioxide (ATO) more effectively damaged the primary CD34+CD38 − cells than CD34+/CD38+ cells in serum-free medium with a cytokines cocktail (Flt3L, SCF, IL-3 and IL-6). (A-C) Quantification of frequencies of Annexin V-positive cells in CD34+CD38− and CD34+CD38+ cells from patient 1 (A), patient 2 (B), patient 3 (C), patient 4 (D). (E) Representative flow cytometric analysis of patient 2 for apoptosis using Annexin V and stem cells markers (CD34, CD38).
Additional file 9: Table S1 . Patients characteristic.
Additional file 10: 
